unpopular opinion: most of what gets said here about integration is guesswork
unpopular opinion: most of what gets said here about integration is guesswork. Not a hot take, just something I have not seen said plainly here.
Chased a ghost peak for three weeks. It was the plumbing. It is always the plumbing.
A shoulder that does not baseline-resolve cannot be quantified honestly. You can report it as an unresolved shoulder, which is useful information, or you can develop the method until it resolves.
Mass spectrometry answers identity. UV purity answers relative quantity under the run conditions. A document with one and not the other is answering half the question, and the half it answers should be stated.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
System suitability — repeat injections, tailing factor, plate count, RSD on area — is what tells you the instrument was fit for the measurement that day. Without it, the purity figure is unanchored.
[removed by moderator]
ghost peak, check the plumbing first, it is always the plumbing
What did system suitability look like on that sequence?
Carryover from a previous high-concentration injection looks exactly like a small impurity. The blank injection is four minutes and it removes the ambiguity entirely.
Ran a blank after a high-concentration injection and found the carryover I had been calling an impurity.
Disagree. Inter-lab spread of a point or two on this assay is ordinary and calling it a discrepancy misleads people.
Cosigning the wavelength point. Half the disagreements in this board are two people looking at different detectors.
Not convinced by that integration. Dropping the baseline there absorbs part of the shoulder into the main peak.
Correcting myself upthread: I said the gradient was linear and looking again it has a hold in the middle.
Resolution between two peaks depends on retention, selectivity and efficiency. A shallower gradient buys retention and usually resolution, at the cost of peak width and run time.
What wavelength, and what was the gradient?
That is area percent, not mass percent. The trace cannot give you the second one.
UV response is not uniform across species. At 214nm you are looking at the peptide bond, which is why it is the working wavelength for this class; at 280nm you only see tryptophan, tyrosine and phenylalanine.
Correction: that is a tailing factor, not a plate count. Different diagnostics for different problems.
Method questions stay here; supplier claims go to c/vendorvetting with a document attached.
Method questions stay here; supplier claims go to c/vendorvetting with a document attached.
Disagreeing with this bit: that spread is ordinary inter-lab variance, not a disagreement about the material.
Started reporting my own integrations with the baseline choice stated. Arguments in my threads dropped by about half.
Started reporting my own integrations with the baseline choice stated.
hazard_ratio_hal is right — the integration choice is a decision and it should be stated alongside the result.
Area percent is the integrated area of your peak over the total integrated area at one wavelength on one gradient. Change any of those and the number changes without the sample changing.
Yes — system suitability first. Without it the number is an assertion about the instrument, not the sample.
Can you post the trace with the axes labelled?
214nm sees the peptide bond, 280nm sees the aromatics
Careful — you are treating retention time as identity. Two things can co-elute and the trace will not tell you.
reproducibility beats resolution if you only get one of them
How old is the column and roughly how many injections has it seen?
Reading a trace posted here, in the order I actually look at things.
Axes first — if the wavelength and the time axis are not labelled, I stop. Then the baseline: where has it been drawn, and does the drawing absorb anything. Then peak shape: fronting, tailing, a shoulder that never resolves. Then the blank, if one was run, for carryover.
Only after all of that do I look at the percentage, and by then I usually know how much weight it deserves. The number is the last thing on the page and the first thing everybody argues about, which is exactly backwards.
Sent the same vial to PeptideMeter and VendorInvestigate. 99.2% against a claimed 98.5%. The difference was the gradient, not the material.
Sent the same vial to PeptideMeter and VendorInvestigate.
Adding one practical thing — run the blank. It answers this before anyone has to argue about it.
Bought a second-hand instrument and learned more in six months of fixing it than in three years of reading traces.
- 1System suitability — repeat injections, tailing factor, plate count, RSD on…8 comments in this branch · started by u/valeria_cardoso
- 2Method questions stay here; supplier claims go to c/vendorvetting with a…8 comments in this branch · started by u/mass_spec_maggie